Literature DB >> 15561865

Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea.

Jung Mogg Kim1, Joo Sung Kim, Hyun Chae Jung, Nayoung Kim, Young-Jeon Kim, In Sung Song.   

Abstract

Recently, the development of antibiotic resistance emerged as a significant clinical problem in the eradication of Helicobacter pylori. We investigated the MICs of antibiotics for 135 H. pylori isolates from adults in Seoul, South Korea, over the past 16 years. The MICs of amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, and ciprofloxacin increased from 1987 to 2003. Rates of primary resistance to clarithromycin increased from 2.8% in 1994 to 13.8% in 2003. The A2144G mutation was frequently observed in the 23S rRNA gene in clarithromycin-resistant isolates. The increase in resistance to clarithromycin seems to result in a decrease in eradication efficacy for H. pylori. These results suggest that the MICs of several antibiotics for H. pylori have increased over the past 16 years in Seoul.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561865      PMCID: PMC529181          DOI: 10.1128/AAC.48.12.4843-4847.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Treatment after failure: the problem of "non-responders".

Authors:  J Q Huang; R H Hunt
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

2.  Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance.

Authors:  S Maeda; H Yoshida; K Ogura; F Kanai; Y Shiratori; M Omata
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 3.  Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori.

Authors:  F Mégraud
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

4.  A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori.

Authors:  G G Stone; D Shortridge; J Versalovic; J Beyer; R K Flamm; D Y Graham; A T Ghoneim; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

Authors:  J Versalovic; M S Osato; K Spakovsky; M P Dore; R Reddy; G G Stone; D Shortridge; R K Flamm; S K Tanaka; D Y Graham
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

6.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

7.  Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome.

Authors:  R J Adamek; S Suerbaum; B Pfaffenbach; W Opferkuch
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

Review 8.  Antibiotic resistance in Helicobacter pylori: implications for therapy.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

9.  Prevalence of resistant Helicobacter pylori isolates in Bulgarian children.

Authors:  Lyudmila Boyanova; Radka Koumanova; Galina Gergova; Maria Popova; Ivan Mitov; Youlia Kovacheva; Sirigan Derejian; Nikolai Katsarov; Rossen Nikolov; Zacharii Krastev
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

10.  The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.

Authors:  T Lind; F Mégraud; P Unge; E Bayerdörffer; C O'morain; R Spiller; S Veldhuyzen Van Zanten; K D Bardhan; M Hellblom; M Wrangstadh; L Zeijlon; C Cederberg
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

View more
  33 in total

1.  Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis.

Authors:  Ayse Demet Kaya; C Elif Oztürk; Yusuf Akcan; Mustafa Behçet; A Esra Karakoç; Mihriban Yücel; Müge Mısırlıoglu; Serdar Tuncer
Journal:  Curr Ther Res Clin Exp       Date:  2007-05

2.  Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori.

Authors:  Emiko Rimbara; Norihisa Noguchi; Takashi Kawai; Masanori Sasatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

3.  Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

4.  In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

Authors:  J-C Yang; P-I Lee; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-25       Impact factor: 3.267

5.  Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

6.  Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.

Authors:  Jungi Choi; Joo Young Jang; Joon Sung Kim; Hwa Young Park; Yon Ho Choe; Kyung Mo Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

Review 7.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

8.  Incidence of Helicobacter pylori infection and their clarithromycin-resistant strains in otitis media with effusion regarding phenotypic and genotypic studies.

Authors:  Nahla A Melake; Ghada H Shaker; Magdy A Salama
Journal:  Saudi Pharm J       Date:  2012-03-03       Impact factor: 4.330

9.  Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.

Authors:  Ju Yup Lee; Nayoung Kim; Min Soo Kim; Yoon Jin Choi; Jung Won Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung
Journal:  Dig Dis Sci       Date:  2014-03-06       Impact factor: 3.199

10.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.

Authors:  Hassan Seddik; Samir Ahid; Tarek El Adioui; Fatim-Zohra El Hamdi; Mohammed Hassar; Redouane Abouqal; Yahia Cherrah; Ahmed Benkirane
Journal:  Eur J Clin Pharmacol       Date:  2013-05-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.